BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32211415)

  • 1. Interstitial Lung Disease-Complicated Anti-MDA5 Antibody in Clinically Amyopathic Dermatomyositis Patients: Report of Two Cases With Distinct Clinical Features.
    Pacot L; Pouchot J; De Prost N; Senant M; Tartour E; Le Pimpec-Barthes F; Israel-Biet D; Dragon-Durey MA
    Front Med (Lausanne); 2020; 7():77. PubMed ID: 32211415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
    Suzuki A; Kondoh Y; Taniguchi H; Tabata K; Kimura T; Kataoka K; Ono K; Hashisako M; Fukuoka J
    Respir Med Case Rep; 2016; 19():5-8. PubMed ID: 27354955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
    Takada T; Aoki A; Asakawa K; Sakagami T; Moriyama H; Narita I; Sato S
    Respir Med; 2015 Sep; 109(9):1174-80. PubMed ID: 26187000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.
    González-Moreno J; Raya-Cruz M; Losada-Lopez I; Cacheda AP; Oliver C; Colom B
    Rheumatol Int; 2018 Jul; 38(7):1293-1296. PubMed ID: 29417209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
    Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
    Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
    [No Abstract]   [Full Text] [Related]  

  • 6. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
    Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
    Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
    Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis.
    Teruya A; Kawamura K; Ichikado K; Sato S; Yasuda Y; Yoshioka M
    Chest; 2013 Dec; 144(6):1934-1936. PubMed ID: 24297126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute lung injury after plasma exchange in a patient with anti-MDA5 antibody-positive, rapidly progressive, interstitial lung disease:A case report.
    Kagawa H; Tsujino K; Yamamoto Y; Iwai A; Hara R; Matsuki T; Fukushima K; Oshitani Y; Yoshimura K; Miki M; Miki K; Kitada S; Mori M; Kida H
    Respir Med Case Rep; 2020; 29():101016. PubMed ID: 32055439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
    Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies.
    Sato S; Kuwana M; Fujita T; Suzuki Y
    Mod Rheumatol; 2012 Aug; 22(4):625-9. PubMed ID: 22124544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
    Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report.
    Yamada K; Asai K; Okamoto A; Watanabe T; Kanazawa H; Ohata M; Ohsawa M; Hirata K
    BMC Res Notes; 2018 Jan; 11(1):34. PubMed ID: 29338781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
    Sato S; Kuwana M; Fujita T; Suzuki Y
    Mod Rheumatol; 2013 May; 23(3):496-502. PubMed ID: 22644102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
    Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations.
    Aoyama J; Hayashi H; Yajima C; Takoi H; Tanaka T; Kashiwada T; Kokuho N; Terasaki Y; Nishikawa A; Gono T; Kuwana M; Saito Y; Abe S; Seike M; Gemma A
    Respir Med Case Rep; 2019; 26():193-196. PubMed ID: 30723666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythematous auricular papules in the fatal cases of anti-MDA5 antibody-positive interstitial lung disease.
    Intapiboon P; Siripaitoon B
    Respir Med Case Rep; 2020; 31():101299. PubMed ID: 33294359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    J Rheumatol; 2017 Mar; 44(3):319-325. PubMed ID: 28089977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.